India's Sun Pharma Q2 net falls 46.5 pct on Protonix provision
MUMBAI Nov 8 (Reuters) - India's Sun Pharmaceutical Industries reported a 46.5 percent drop in quarterly net profit after it set aside 5.84 billion rupees ($108.02 million) towards a possible compensation in a patent dispute case related to drug Protonix.
The Mumbai-based drugmaker said consolidated net profit fell to 3.2 billion rupees during fiscal second quarter ended September from 5.98 billion rupees a year earlier. Net sales rose 40.2 percent to 26.57 billion rupees.
Analysts had estimated the net profit at 7.68 billion rupees, according to Thomson Reuters I/B/E/S. ($1 = 54.0650 Indian rupees) (Reporting by Kaustubh Kulkarni; Editing by Jijo Jacob)
- Hong Kong protesters stockpile supplies, fear fresh police advance |
- Kurds seize Iraq/Syria border post; Sunni tribe joins fight against Islamic State |
- Protesters stay out on Hong Kong streets, defying Beijing |
- Special Report: Islamic State uses grain to tighten grip in Iraq
- EBay follows Icahn's advice, plans PayPal spinoff in 2015 |